Therapeutic Advances in Hematology

Scope & Guideline

Unlocking new horizons in hematological advancements.

Introduction

Delve into the academic richness of Therapeutic Advances in Hematology with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN2040-6207
PublisherSAGE PUBLICATIONS LTD
Support Open AccessYes
CountryUnited States
TypeJournal
Convergefrom 2010 to 2016, from 2018 to 2024
AbbreviationTHER ADV HEMATOL / Ther. Adv. Hematol.
Frequency1 issue/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND

Aims and Scopes

Therapeutic Advances in Hematology focuses on advancing the understanding and treatment of hematological disorders through innovative research and clinical studies. The journal emphasizes multidisciplinary approaches and encourages contributions that enhance patient care and treatment outcomes.
  1. Hematological Malignancies:
    Research on various hematological malignancies, including acute myeloid leukemia (AML), multiple myeloma, and lymphomas, focusing on novel therapeutic strategies and clinical outcomes.
  2. Transfusion Medicine and Hemostasis:
    Exploration of topics related to transfusion practices, management of bleeding disorders, and advancements in therapies for hemophilia and thrombocytopenia.
  3. Stem Cell Transplantation and Gene Therapy:
    Studies addressing the role of hematopoietic stem cell transplantation (HSCT), including conditioning regimens, donor selection, and the integration of gene therapy in treating hematological diseases.
  4. Patient-Reported Outcomes and Quality of Life:
    Research that evaluates the impact of hematological diseases and their treatments on patients' quality of life, incorporating patient-reported outcomes to inform treatment decisions.
  5. Innovative Treatment Modalities:
    Investigation into new treatment modalities such as CAR-T therapy, bispecific antibodies, and targeted therapies, with a focus on their efficacy and safety in various hematological conditions.
The journal has demonstrated a dynamic evolution in its research themes, with several emerging topics reflecting the latest advancements and priorities in hematology.
  1. Targeted and Personalized Therapies:
    A growing emphasis on targeted therapies, such as B-cell maturation antigen (BCMA) targeting in multiple myeloma, reflects the shift towards personalized medicine tailored to individual genetic profiles.
  2. Immunotherapy Advances:
    The rise of immunotherapeutic strategies, including CAR-T cell therapy and bispecific antibodies, indicates a significant trend towards harnessing the immune system to combat hematological malignancies.
  3. Real-World Evidence and Patient Experience:
    Increased attention to real-world evidence and patient-reported outcomes highlights the importance of understanding treatment impacts from the patient's perspective, influencing clinical practice.
  4. Innovations in Hematopoietic Stem Cell Transplantation:
    Research focusing on advancements in HSCT techniques, including the use of haploidentical donors and novel conditioning regimens, is becoming more prominent as these methods improve patient outcomes.
  5. Management of Rare Hematological Disorders:
    There is an emerging focus on the management and treatment of rare hematological conditions, such as aplastic anemia and paroxysmal nocturnal hemoglobinuria, addressing unmet medical needs.

Declining or Waning

While Therapeutic Advances in Hematology continues to publish impactful research, certain themes appear to be declining in prominence over recent years, potentially reflecting shifts in research focus or advancements in treatment options.
  1. Traditional Chemotherapy Approaches:
    The focus on traditional chemotherapy regimens appears to be waning, as newer targeted therapies and immunotherapies gain prominence in treatment paradigms for hematological malignancies.
  2. Historical Case Reports:
    The journal has seen a decrease in the publication of historical or anecdotal case reports, as the emphasis shifts towards larger, evidence-based studies and clinical trials.
  3. Generalized Treatment Guidelines:
    There is less emphasis on broad treatment guidelines that do not consider individual patient characteristics, as precision medicine and personalized treatment strategies become more prevalent.
  4. Epidemiological Studies:
    Research focused solely on epidemiological data without direct clinical implications seems to be less prioritized, as the journal emphasizes studies that directly impact treatment outcomes and patient care.

Similar Journals

BLOOD REVIEWS

Elevating knowledge in blood disorders and cancer care.
Publisher: CHURCHILL LIVINGSTONEISSN: 0268-960XFrequency: 6 issues/year

BLOOD REVIEWS is a highly regarded journal published by Churchill Livingstone, specializing in the fields of Hematology and Oncology. With an impressive Q1 ranking in both disciplines and placing in the top 10% of its peer categories according to Scopus metrics, it provides an essential platform for the dissemination of cutting-edge research and reviews pertaining to blood disorders and cancer treatment. Since its inception in 1987 and continuing through 2024, the journal has established itself as a cornerstone for healthcare professionals, researchers, and students who seek to advance their understanding of hematologic and oncologic topics. While not an open-access journal, BLOOD REVIEWS retains a reputation for delivering high-quality, peer-reviewed articles that foster dialogue and innovation within the scientific community. For those in the United States and beyond, the journal serves as a vital resource, housed at the Journal Production Department in Edinburgh, Scotland, ensuring accessibility and a global reach in its critical academic contributions.

BONE MARROW TRANSPLANTATION

Empowering the Future of Bone Marrow Medicine.
Publisher: SPRINGERNATUREISSN: 0268-3369Frequency: 12 issues/year

BONE MARROW TRANSPLANTATION, published by SpringerNature, stands as a leading journal in the fields of Hematology and Transplantation, as evidenced by its recognition in the Q1 category for both disciplines according to 2023 rankings. With an impressive impact factor and notable Scopus rankings—7th out of 54 in Medicine Transplantation and 25th out of 137 in Medicine Hematology—this journal is instrumental for researchers and professionals dedicated to advancements in bone marrow transplantation practices and research. Established in 1986, the journal publishes original research, clinical studies, and reviews that push the boundaries of current knowledge, making it essential reading for those looking to stay abreast of the latest developments in the field. Although offering limited Open Access options, BONE MARROW TRANSPLANTATION reaches a broad audience and furthers a global dialogue on best practices and innovative approaches in transplantation medicine. Its address in London, UK positions it at the heart of international research collaboration, fostering connections among scientists, clinicians, and students alike.

Journal of Hematology & Oncology

Elevating Knowledge in Cancer and Hematological Studies
Publisher: BMCISSN: Frequency: 1 issue/year

Journal of Hematology & Oncology, published by BMC, is a leading open-access journal dedicated to the dynamic fields of hematology and oncology, with a continuous publication record since 2008. Based in the United Kingdom, this prestigious journal provides a platform for groundbreaking research, encompassing topics that span cancer research, hematological disorders, and molecular biology. With a remarkable Q1 ranking in multiple categories including Cancer Research, Hematology, Molecular Biology, and Oncology for 2023, it stands as a significant contributor to the scientific community. The journal's rigorous peer-review process ensures the dissemination of high-quality studies that drive advancements in these critical areas of medicine, boasting an impressive Scopus rank in the top echelons of its fields. As an open-access publication, it promotes widespread accessibility and sharing of knowledge, making it an indispensable resource for researchers, clinicians, and students striving to make advancements in understanding and treating hematological and oncological diseases.

Indian Journal of Hematology and Blood Transfusion

Inspiring Progress in Blood Health Through Rigorous Research
Publisher: SPRINGER INDIAISSN: 0971-4502Frequency: 4 issues/year

Indian Journal of Hematology and Blood Transfusion, published by SPRINGER INDIA, serves as a leading platform for disseminating original research, reviews, and case studies in the field of hematology. With an ISSN of 0971-4502 and E-ISSN 0974-0449, this journal has been instrumental in advancing knowledge from 2000 to 2024, providing insights into critical issues surrounding blood disorders and transfusion practices. Currently ranked in the Q3 category for Hematology for 2023, it reflects a commitment to high-quality scientific content amidst a competitive landscape where it ranks 97/137 in Scopus for Medicine - Hematology, placing it in the 29th percentile of its peers. The journal primarily addresses a diverse readership, including researchers, healthcare professionals, and students, aiming to foster innovation and collaboration within the field. Although it operates under a subscription model, access options for individual articles and institutional subscriptions ensure that valuable research is disseminated widely to enhance medical practice and education in hematology.

Mediterranean Journal of Hematology and Infectious Diseases

Pioneering the future of hematology and infectious diseases.
Publisher: MATTIOLI 1885ISSN: Frequency: 1 issue/year

Mediterranean Journal of Hematology and Infectious Diseases is a distinguished open access journal published by MATTIOLI 1885, dedicated to advancing the field of hematology and infectious diseases. Since its inception in 2009, the journal has provided a platform for researchers and practitioners to disseminate innovative findings, foster scholarly discourse, and enhance our understanding of these critical medical disciplines. With an impact factor reflecting its scholarly influence, it is recognized in the Q3 quartile for both Hematology and Infectious Diseases categories as of 2023. The journal's commitment to open access ensures that high-quality research is accessible to a global audience, contributing to the improvement of clinical practices and public health. Located in Fidenza, Italy, the journal continues to support converged research efforts from 2010 to 2024, making it an essential resource for academics, clinicians, and students in the medical community.

Egyptian Journal of Haematology

Empowering Hematologists with Cutting-Edge Research
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 1110-1067Frequency: 4 issues/year

The Egyptian Journal of Haematology, published by WOLTERS KLUWER MEDKNOW PUBLICATIONS, stands as a pivotal resource in the field of hematology, particularly within the context of Egypt and the broader Middle Eastern region. This journal is dedicated to disseminating high-quality research that explores the latest advancements in blood disorders, hematologic malignancies, and transfusion medicine. With a focus on original research, case studies, and reviews, it aims to provide a comprehensive platform for hematologists, researchers, and healthcare professionals to enhance their understanding and management of hematological conditions. Although it is not an open-access journal, the rigorous peer-review process ensures that only the most impactful studies are published, contributing to the journal's reputation in the academic community. The Egyptian Journal of Haematology serves as an essential tool for advancing knowledge, improving clinical outcomes, and fostering collaboration among experts in the field.

Hematology-American Society of Hematology Education Program

Advancing Hematology through Expert Education
Publisher: AMER SOC HEMATOLOGYISSN: 1520-4391Frequency: 1 issue/year

Hematology-American Society of Hematology Education Program is a premier peer-reviewed journal dedicated to advancing the field of hematology through comprehensive educational content. Published by the American Society of Hematology, this journal plays a crucial role in disseminating knowledge to researchers, clinicians, and students in hematology and related disciplines. With an impressive Q1 status in the field, it ranks among the top journals at the forefront of hematological research, as evidenced by its 60th percentile ranking in Scopus' Medicine - Hematology category. Although it does not offer open access, the journal provides invaluable insights and educational resources from leading experts, focusing on the latest advancements, treatment protocols, and evolving understanding of blood disorders. Covering a wide range of topics, from basic research to clinical applications, this journal is essential for anyone seeking to deepen their expertise and stay informed on the latest developments in hematology. For further engagement, readers can access insightful articles published since 2001, ensuring a rich repository of knowledge for ongoing research and clinical excellence.

Experimental Hematology & Oncology

Transforming Research into Breakthroughs in Hematology & Oncology
Publisher: BMCISSN: Frequency: 1 issue/year

Experimental Hematology & Oncology is a premier journal published by BMC, dedicated to advancing knowledge in the fields of hematology, oncology, and cancer research. Since its inception in 2012, this Open Access journal has emerged as a vital resource for researchers and healthcare professionals, fostering the dissemination of high-quality research that enhances our understanding of blood disorders and malignancies. With impressive rankings in Quarters 1 of key categories including Cancer Research, Hematology, and Oncology, it holds significant prestige, evidenced by its Scopus rankings: #42/404 in Medicine (Oncology) and #17/137 in Medicine (Hematology). The journal aims to publish cutting-edge studies, reviews, and perspectives that contribute to the evolution of therapeutic strategies and innovative treatment modalities. Researchers and practitioners alike will find this journal indispensable for staying at the forefront of breakthroughs in hematological and oncological research.

Turkish Journal of Hematology

Championing open access to vital hematology knowledge.
Publisher: GALENOS PUBL HOUSEISSN: 1300-7777Frequency: 4 issues/year

Turkish Journal of Hematology is an esteemed publication dedicated to advancing the field of hematology, producing influential research since its inception in 1999 under the auspices of GALENOS PUBL HOUSE. With an Open Access model, it facilitates widespread dissemination of knowledge, allowing researchers, clinicians, and students to stay abreast of the latest developments in blood disorders and treatments. With an ISSN of 1300-7777 and an E-ISSN of 1308-5263, the journal holds a commendable position in the academic community, evidenced by its 2023 Q3 ranking within the hematology category and its standing at #80 out of 137 in the Scopus database, placing it in the 41st percentile. Covering a wide scope of topics within hematology, this journal serves as a critical resource for disseminating innovative research and clinical practices pertinent to the ongoing challenges faced in this vital area of medicine. With its continuous publication until 2024, Turkish Journal of Hematology remains a beacon for enhancing the understanding and treatment of hematological conditions within the Turkish and global medical communities.

ANNALS OF HEMATOLOGY

Unveiling innovative methodologies for blood health.
Publisher: SPRINGERISSN: 0939-5555Frequency: 12 issues/year

ANNALS OF HEMATOLOGY, published by Springer in Germany, stands as a premier platform for advancing knowledge in the field of hematology and medicine at large. With a significant impact factor and recognized rankings—Q2 in Hematology and Q1 in Medicine (miscellaneous) as of 2023—this journal is pivotal for researchers, clinicians, and students who are keen on exploring the latest developments in blood disorders, treatments, and innovative methodologies. Its broad scope encompasses original research, reviews, and discussions that aim to foster interdisciplinary dialogue, ensuring that the latest findings and theories are accessible to the scientific community. Although not an open-access journal, its rigorous peer-review process guarantees high-quality contributions, thereby solidifying its reputation as a vital resource in the hematological field. Founded in 1991, the ANNALS OF HEMATOLOGY continues to evolve, converging invaluable insights from both basic and clinical research until 2024. For those dedicated to improving patient outcomes and advancing hematological science, this journal remains an essential reference.